AN2 Therapeutics Files 8-K: Material Agreement
Ticker: ANTX · Form: 8-K · Filed: Aug 19, 2024 · CIK: 1880438
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
TL;DR
AN2 Therapeutics filed an 8-K on 8/15, indicating a major deal and changes to shareholder rights.
AI Summary
AN2 Therapeutics, Inc. announced on August 15, 2024, that it entered into a Material Definitive Agreement. The filing also indicates modifications to the rights of security holders and amendments to its articles of incorporation or bylaws. Specific details regarding the agreement, modifications, or amendments, including any associated dollar amounts or precise dates beyond August 15, 2024, are not provided in this summary excerpt.
Why It Matters
This filing signals a significant corporate event for AN2 Therapeutics, potentially impacting its operations, financial structure, or shareholder rights.
Risk Assessment
Risk Level: medium — The filing indicates material changes and agreements, which inherently carry risk, but the specific nature and impact are not detailed.
Key Players & Entities
- AN2 Therapeutics, Inc. (company) — Registrant
- August 15, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 1800 El Camino Real, Suite D (address) — Business Address
- Menlo Park (city) — Business Address City
FAQ
What is the nature of the Material Definitive Agreement entered into by AN2 Therapeutics?
The provided excerpt does not specify the details of the Material Definitive Agreement.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on August 15, 2024.
What are the key items reported in this 8-K filing?
The key items reported are Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, and Financial Statements and Exhibits.
Where is AN2 Therapeutics, Inc. incorporated?
AN2 Therapeutics, Inc. is incorporated in Delaware.
What is the business address of AN2 Therapeutics, Inc.?
The business address is 1800 El Camino Real, Suite D, Menlo Park, CA 94027.
Filing Stats: 2,698 words · 11 min read · ~9 pages · Grade level 15.4 · Accepted 2024-08-19 06:04:59
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share ANTX The Nasdaq
- $6.50 — ferred "), of the Company at a price of $6.50 per one one-thousandth of a share of Se
- $1.00 — ferential quarterly dividend payment of $1.00 per share or, if greater, an aggregate
- $1,000 — mum preferential liquidation payment of $1,000 per share (plus any accrued but unpaid
- $0.01 — n whole, but not in part, at a price of $0.01 per Right (the " Redemption Price ") by
Filing Documents
- d879523d8k.htm (8-K) — 46KB
- d879523dex31.htm (EX-3.1) — 29KB
- d879523dex41.htm (EX-4.1) — 267KB
- d879523dex991.htm (EX-99.1) — 10KB
- g879523g0818100647176.jpg (GRAPHIC) — 3KB
- 0001193125-24-202430.txt ( ) — 603KB
- antx-20240815.xsd (EX-101.SCH) — 4KB
- antx-20240815_def.xml (EX-101.DEF) — 14KB
- antx-20240815_lab.xml (EX-101.LAB) — 24KB
- antx-20240815_pre.xml (EX-101.PRE) — 15KB
- d879523d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . 3.1 Certificate of Designations of Series A Junior Participating Preferred Stock of AN2 Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on August 15, 2024. 4.1 Rights Agreement, dated as of August 15, 2024, between AN2 Therapeutics, Inc. and Equiniti Trust Company, LLC, which includes the Form of Certificate of Designations of Series A Junior Participating Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C. 99.1 Press Release of AN2 Therapeutics, Inc., dated August 16, 2024. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AN2 Therapeutics, Inc. Date: August 19, 2024 /s/ Eric Easom Eric Easom Chief Executive Officer and Director